GT
NVCR icon

Glenmede Trust’s NovoCure NVCR Stock Holding History

Glenmede Trust’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100
Closed -$11K – 1888
2020
Q3 		$11K Sell
100
-12
-11% -$960 ﹤0.01% 1842
2020
Q2 		$6K Sell
112
-2,857
-96% -$188K ﹤0.01% 2035
2020
Q1 		$249K Hold
2,969
– – ﹤0.01% 1119
2019
Q4 		$249K Buy
2,969
+107
+4% +$8.64K ﹤0.01% 1119
2019
Q3 		$213 Buy
2,862
+1,662
+139% +$133K ﹤0.01% 1139
2019
Q2 		$75 Buy
+1,200
New +$60.8K ﹤0.01% 1507

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Glenmede Trust's NVCR Position: Q4 2020 in Review

Glenmede Trust sold out of NovoCure (NVCR) in Q4 2020, closing a stake of 100 shares — an estimated $11K sold.

Glenmede Trust first reported a position in NVCR in Q2 2019 and held it in 6 quarters. The position peaked at $249K in Q1 2020. 356 funds tracked by Wall St. Rank hold NVCR as of Q4 2020.

  • Glenmede Trust reported no remaining NovoCure position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 100 NovoCure shares in Q4 2020, an estimated $11K.
  • Glenmede Trust first reported a position in NovoCure in Q2 2019 and held it in 6 quarters.
  • Glenmede Trust's NovoCure position peaked at $249K in Q1 2020.
  • 356 funds tracked by Wall St. Rank held NovoCure as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.